Some serious risks include hypoglycemia, thyroid tumors, altered immune responses, and gallbladder disease
Regulatory and Practical Limitations: NA-931 is still investigational and not approved for any use
Zepbound is a dual GIP and GLP-1 receptor agonist, which means it activates both incretin pathways to enhance blood sugar control and support effective, long-term weight loss
This gives the dermis a head start on collagen production before significant volume loss has occurred
Gentle abdominal massage may also help
Marginal structural models were used to evaluate the association between GLP-1RAs and MACE risk, accounting for time-varying confounding using inverse probability weighting, although residual confounding cannot be fully excluded